Benchmarking Investigator Payments -

Published: Q4, 2012 | Pages: 69

It goes without saying that Sponsors and CROs can’t afford to get the investigator payment level wrong. The downsides of not paying market-rate investigator fees impact both the financial health of the organization and the ability to recruit high-performing and experienced sites. Pay too much and your budget evaporates, pay too little and it will be difficult to recruit experienced sites.
Major Report Sections:

  • Benchmarking Investigator Fees, including: Therapeutic area averages, phase comparison by specialty/TA, compoud type compensation by specialty/TA
  • Specialty/Therapeutic Area Analysis
  • Investigator Payment Dynamics, including: Drivers of investigator fees and Investigator payment models
  • Site and Respondent Demographics
Actionable Insight:

  • Benchmark your investigator payments against industry averages to establish and negotiate contracts 
  • Understand how “trial complexity” and “length of study” impact investigators’ willingness to participate and the impact on investigator fees 
  • Institute more realistic feasibility assessments and site start-up timing by understanding which therapeutic areas, phases, and types of products carry the highest cost
Therapeutic Areas Included:

Infectious Diseases
Internal Medicine
Metabolic Diseases
Women’s Health
Analysis By:
Therapeutic area
Phase of development (I, II, III, IV)
Compound type (Biologic, Biosimilar, Me-too, Generic, Novel)
Benchmarking Investigator Payments1
Copyright and Usage Guidelines6
Executive Summary10
Average compensation per patient10
Average compensation across phases11
Average compensation across compound types11
Phase compensation by therapeutic area12
Compound type compensation by therapeutic area13
Appeal of innovative compounds14
Milestone payment plans14
Payment negotiation atmosphere14
Summary: trial activity vs. study concentration by therapeutic area15
Impact of study length and complexity on investigator fees16
Recommendations tear sheet17
Benchmarking Investigator Fees19
Therapeutic area average investigator payment19
Phase comparison by specialty/ therapeutic areas20
Phase I20
Phase II21
Phase III22
Phase IV23
Compound type compensation by specialty/ therapeutic area24
Specialty/ Therapeutic Area Analysis29
Compensation per patient by phase29
Compensation per patient by compound type30
Compensation per patient by phase31
Compensation per patient by compound type32
Compensation per patient by phase33
Compensation per patient by compound type34
Infectious Diseases35
Compensation per patient by phase35
Compensation per patient by compound type36
Internal Medicine37
Compensation per patient by phase37
Compensation per patient by compound type38
Metabolic Diseases39
Compensation per patient by phase39
Compensation per patient by compound type40
Musculoskeletal / Arthritis41
Compensation per patient by phase41
Compensation per patient by compound type42
Compensation per patient by phase43
Compensation per patient by compound type44
Compensation per patient by phase45
Compensation per patient by compound type46
Respiratory / Allergy47
Compensation per patient by phase47
Compensation per patient by compound type48
Women’s Health49
Compensation per patient by phase49
Compensation per patient by compound type50
Investigator Payment Dynamics51
Number of clinical trials managed51
Site specialty/ therapeutic experience in past 24 months52
Number of studies managed in past 24 months by therapeutic area53
Feedback on the amount of clinical trials involved in54
Drivers of Investigator Fees55
Most influential motivators for site participation in a study55
Study characteristics that drive higher fees56
Appeal of innovative compound studies56
Likelihood to participate in complex clinical trials57
How length of study impacts investigator fees58
How study complexity impacts investigator fees58
Investigator payment models59
Payment model use59
Milestone trigger payment use60
Payment milestone preference61
Site and Respondent Demographics62
Presence of site compensation manager62
Time distribution between non-clinical trials vs. clinical trial patients62
Proportion of revenue from clinical trials63
Clinical trials under Master Service Agreement (MSA)64
Currently conducting clinical research65
Primary role65
Years in current position66
Geographic location66
Primary office setting67